Global Vaccines Market size to exceed $72.5bn by 2025

Global Vaccines Market size is set to exceed USD 72.5 billion by 2025; according to a new research report by Global Market Insights, Inc.
 

Rising pervasiveness of infectious and chronic diseases across the globe will offer robust potential to the global vaccines market growth during the forecast timeframe. As per the World Health Organization, around 5.72 billion people across the globe are at high risk of various endemic diseases. Additionally, in 2017, about 36.9 million were affected due to HIV/AIDS infection, of which about 940,000 people died due to illnesses associated with the infection. AIDS is a fatal infection and development of vaccine for its effective prevention is crucial, thereby providing lucrative opportunities to global vaccine market growth.

 


Request Sample Buy NowInquiry Before Buying 

 

Growing funding for development & advancement in vaccines along with implementation of numerous programs will augment vaccines industry growth over the foreseeable future. The European Vaccine Initiative is aimed at supporting vaccine development through funding and includes institutes such as Biomedical Primate Research Centre, Jenner Vaccine Foundation and Institut Pasteur, among few others. The initiative works especially for resource-deprived and poor countries. Similarly, PATH's Malaria Vaccine Initiative (MVI) is a program by non-profit organization that works along with government, academics and private industry to develop vaccines for malaria. Thus, such initiatives and programs will pose to be a high impacting factor for vaccines business growth over the analysis period.
 

Browse key industry insights spread across 192 pages with 216 market data tables & 9 figures & charts from the report, “Global Vaccines Market Size By Age Group (Pediatric, Adult), By Technology (Conjugate, Attenuated, Inactivated, Recombinant, Toxoid), By Disease (Cancer, Hepatitis, Pneumococcal Disease, DTP, Dengue, Influenza, Human Papilloma Virus, Meningococcal Disease, Polio, Rotavirus), Regional Outlook (U.S., Canada, Germany, UK, Spain, Russia, Italy, France, China, Japan, India, South Korea, Australia, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE, Qatar, Egypt), Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/vaccines-market
 

Adult vaccines market accounted for USD 16.3 billion in the year 2018. Growing adoption of adult vaccines for preventing incidence of human papillomavirus, hepatitis B, mumps,  measles, meningococcal disease, hepatitis A, chickenpox, and rubella will drive adult vaccines market over the forecast timeframe. Furthermore, several initiatives undertaken by the government and other organizations to create awareness about vaccine preventable diseases will encourage the adoption of vaccines among adults. Such strategies include initiation of The National Adult Immunization Plan in the U.S. leading to considerable rise in adoption of vaccines among adult population.
 

Conjugate vaccines market held over 40% market share in 2018 and is forecast to grow at a rapid rate over the projection timeframe. According to the WHO, conjugate vaccines are proved to be safe and quite effective. For instance, the conjugate typhoid vaccine provides enhanced protection against the diseases for infants aged below two years of age, in comparison with other available vaccines. It also recommends including the vaccine for routine vaccination programmes. In addition, conjugate vaccines offer enhanced immunogenicity, thereby impelling the segmental growth.
 

Vaccines market for prevention of pneumococcal diseases held major revenue share and is estimated to progress at 9.6% CAGR over the forecast period. Pneumococcal diseases are the most commonly occurring diseases with high mortality rate. Thus, increasing vaccination and immunization against pneumococcal diseases will spur the segmental growth. In addition, numerous industry players are concentrating on introduction of novel vaccines against such diseases, thereby propelling the segmental revenue.
 

Italy accounted for 10% market share of Europe market in 2018. Increasing incidence of infectious diseases including measles will act as major driving factor for Italy vaccines market growth. Government’s efforts to escalate the vaccination rate in the country by implementing laws including compulsory vaccination against 10 diseases for children enrolling in state-run schools will propel the industry growth over the projected timeframe.
 

Brazil vaccines market will expand at 9.6% CAGR during the forecast period. Numerous initiatives undertaken by Brazilian government and other organizations such as the Pan American Health Organization (PAHO) and WHO to rise vaccination rate in the country coupled with growing prevalence of infectious diseases including the yellow fever will drive the business growth over the coming years. In January 2018, Brazil launched a mass immunization campaign delivering fractional doses of yellow fever vaccine to individuals residing in 69 municipalities in states of São Paulo and Rio de Janeiro. Such initiatives will support the growth of vaccines market.
 

Sanofi, GlaxoSmithKline, Pfizer and Merck & Co., Inc. are few of the major players operating in the global vaccines industry. Launch of novel vaccine therapies and strategic alliances are the key strategies adopted by these firms to enhance their market footprint and achieve significant market share. For instance, in July 2019, the National Institutes of Health and Partners announced its plan regarding conduct of phase three HIV vaccine efficacy trial, Mosaico that is sponsored by Johnson & Johnson across Europe, North America and South America.
 

Inquiry Before BuyingRequest Sample
 

Global vaccines market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD billion from 2014 to 2025, for the following segments:
 

By Age Group (USD Million)

  • Pediatric
  • Adult

By Technology (USD Million)

  • Attenuated
  • Toxoid
  • Conjugate
  • Inactivated & subunit
  • Recombinant
  • Others

By Disease (USD Million)

  • Cancer
  • Hepatitis
  • Pneumococcal disease
  • DTP
  • Dengue
  • Influenza
  • Human papilloma virus
  • Meningococcal disease
  • Polio
  • Rotavirus
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Russia
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • Egypt

 

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X